** Scholar Rock's shares SRRK.O up 3.4% premarket
** Co says U.S. FDA accepts SRRK's drug, apitegromab, for priority review with a decision expected by Sept 22; EU's medicines regulator has also accepted drug for review
** Co's drug treats spinal muscular atrophy, which stops production of a protein necessary for neuromuscular development and leaves children too weak to walk, talk and swallow
** In a late-stage study, patients given apitegromab saw better improvement in motor function than those given a placebo
** As of last close, SRRK up nearly 17% so far this year
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。